Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ACE inhibitor drug used to delay heart failure as effective in blacks as whites

19.07.2002


Dr. Daniel Dries, left, and Dr. Mark Drazner found that enalapril, an ACE inhibitor commonly given to patients with heart failure, is just as effective for black patients with heart failure as it is for white patients.


A drug widely used to treat patients with heart failure is as effective for black patients as it is for white patients, according to researchers at UT Southwestern Medical Center at Dallas.

The results of this analysis do not support the hypothesis that black patients with heart failure may not respond as well to angiotensin-converting enzyme (ACE) inhibitors as white patients with heart failure, said Dr. Daniel Dries, lead author of the study in today’s issue of the Journal of the American College of Cardiology and assistant professor of internal medicine at UT Southwestern.

"Although the black participants responded equally well to the ACE-inhibitor as white participants, they still had overall increased rates of progression to heart failure," Dries said. "The precise explanation for the racial differences in the natural history of asymptomatic reductions in pump function is not known, but these data indicate that it is not explained by racial differences in response to ACE-inhibitor therapy."



A retrospective analysis of 4,054 study participants involved in the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial found that enalapril, an ACE-inhibitor commonly given to patients with heart failure, is effective at reducing the development of heart failure in both population groups. Results of the SOLVD Prevention Trial were originally published in 1992 in The New England Journal of Medicine.

A 2001 report, in which Dries participated, suggested that enalapril was less effective in reducing the risk of hospitalization for heart failure in blacks compared to whites. There was no evidence for racial differences in enalapril’s ability to reduce the risk of death. The analysis reported today focused specifically on the ability of ACE-inhibitor therapy to delay the development of heart failure in patients with asymptomatic reductions in heart function.

"The previous study found evidence for racial differences in response to ACE-inhibitor therapy only for a single clinical endpoint - the risk for hospitalization - which can be influenced by a variety of environmental and social factors," said Dries. "In this study, the benefit of enalapril was consistent and robust in reducing a spectrum of clinical endpoints indicating disease progression in both black and white participants."

Dr. Mark Drazner, a co-author of the study and assistant professor of internal medicine, said the present study showed that enalapril prevented the development of heart failure in black and white patients equally well.

"Coupling this with previous data showing that enalapril resulted in comparable reductions in mortality in black and white patients with heart failure, we believe that ACE-inhibitors should remain a cornerstone of therapy in patients with a weak or failing heart, irrespective of their race or ethnicity," Drazner said.

Dr. Mark Strong, assistant professor of internal medicine at UT Southwestern, also participated in the study.

Amy Shields | EurekAlert

More articles from Interdisciplinary Research:

nachricht Lego-like wall produces acoustic holograms
17.10.2016 | Duke University

nachricht New evidence on terrestrial and oceanic responses to climate change over last millennium
11.10.2016 | University of Granada

All articles from Interdisciplinary Research >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

Shape matters when light meets atom

05.12.2016 | Physics and Astronomy

Researchers uncover protein-based “cancer signature”

05.12.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>